首页> 外文OA文献 >Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases.
【2h】

Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases.

机译:合并阿莫西林-克拉维酸合并肝炎15例报道。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fifteen cases of hepatitis related to a combination of amoxycillin and clavulanic acid are reported. Most patients were aged 60 years or more and there were more men than women (sex ratio 4:1). The amoxycillin-clavulanic acid had been given at doses ranging from 0.5 to 6 g/day (mean 2 g/day) for seven to 60 days (mean 18 days). In 11 cases, the first symptoms appeared one to four weeks after stopping treatment. Jaundice was observed in all patients and was frequently associated with pruritus. Serum aminotransferase activities were increased in all patients and were generally two to 10 times the upper limit of normal. Serum alkaline phosphatase activity was considerably increased, from two to seven times the upper limit of normal. Histological examination of the liver, performed in seven patients, showed centri- or panlobular cholestasis in all cases, associated with granulomatous hepatitis in one. The prognosis of amoxycillin-clavulanic acid induced hepatitis seemed to be good. None of the patients exhibited biological or clinical features of hepatic failure and the course of the disease was characterised by the resolution of jaundice within one to eight weeks and a complete recovery within four to 16 weeks. Taking into account the number of treated subjects and reported cases, we estimated the risk of developing hepatitis with this drug combination to be very low, probably below 1/100,000. Our data suggest that the risk of hepatotoxicity may be increased in elderly men given lengthy treatment. The association of hepatitis and signs of hypersensitivity may suggest an immunoallergic mechanism of hepatotoxicity in some patients.
机译:据报道有十五例肝炎与阿莫西林和克拉维酸联合使用有关。大多数患者年龄在60岁以上,男性多于女性(性别比4:1)。阿莫西林-克拉维酸的剂量范围为0.5至6克/天(平均2克/天),持续7至60天(平均18天)。在11例患者中,停止治疗后一到四个星期出现了最初的症状。在所有患者中均观察到黄疸,并经常伴有瘙痒。所有患者的血清氨基转移酶活性均升高,通常是正常上限的2至10倍。血清碱性磷酸酶活性显着增加,从正常上限的两倍增加到七倍。对7例患者进行的肝脏组织学检查显示,所有病例中均存在中心或小叶胆汁淤积,其中1例与肉芽肿性肝炎有关。阿莫西林-克拉维酸诱导的肝炎的预后似乎很好。没有患者表现出肝功能衰竭的生物学或临床特征,并且该疾病的病程以在1至8周内黄疸消退并在4至16周内完全康复为特征。考虑到接受治疗的受试者和报告的病例数,我们估计使用这种药物联合治疗患肝炎的风险非常低,可能低于1 / 100,000。我们的数据表明,接受长期治疗的老年男性可能会增加肝毒性的风险。肝炎和超敏反应的迹象可能表明某些患者有肝毒性的免疫过敏机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号